This is a basic profile of an NZX50 listed company. It is not investment advice. We recommend you contact a qualified adviser if you need more information.
Fisher & Paykel Healthcare
Directory
| NZX code: | FPH |
| Short name: | Fisher & Paykel Healthcare |
| Legal name: | Fisher & Paykel Healthcare Corporation Limited |
| Industry sector: | Healthcare equipment |
| NZX50 rank: | 1 of 50 |
| Head office address: | 15 Maurice Paykel Place, Auckland, 1061 |
| Chairman: | Neville Mitchell |
| Chief executive: | Lewis Gradon |
| Financial year ended: | March |
| Locations: | New Zealand, Australia |
| Auditor: | Pwc |
| Bankers: | [not revealed] |
Fisher and Paykel Healthcare
Select chart tabs
Financial statement history
A. Recent trading and performance summary:
| Total revenue |
NPAT | Dividend per share |
|
| fye March | bln | mln | cents |
| 2018 | $1.0 | $190 | 21 |
| 2019 | $1.1 | $209 | 23 |
| 2020 | $1.3 | $287 | 28 |
| 2021 | $2.0 | $524 | 38 |
| 2022 | $1.7 | $377 | 40 |
| 2023 | $1.6 | $250 | 41 |
| 2024 | $1.7 | $133 | 23 |
| 2025 | $2.0 | $377 | 23 |
B. Recent financial position summary:
| Total assets |
Total Liabilities |
Equity ratio |
|
| fye March | bln | mln | % |
| 2018 | $1.0 | $264 | 74 |
| 2019 | $1.2 | $294 | 76 |
| 2020 | $1.4 | $461 | 68 |
| 2021 | $2.1 | $554 | 73 |
| 2022 | $2.1 | $427 | 80 |
| 2023 | $2.2 | $451 | 80 |
| 2024 | $2.3 | $523 | 77 |
| 2025 | $2.6 | $660 | 74 |
C. Recent cash flows and positions:
| Cash inflows |
Cash outflows |
Cash and equiv. at year end |
|
| fye March | mln | mln | mln |
| 2018 | $248 | $278 | $16 |
| 2019 | $253 | $239 | $31 |
| 2020 | $321 | $315 | $36 |
| 2021 | $625 | $575 | $85 |
| 2022 | $324 | $325 | $85 |
| 2023 | $238 | $208 | $117 |
| 2024 | $430 | $339 | $81 |
| 2025 | $549 | $371 | $260 |
D. Recent key ratio analysis:
| Earnings per share |
Price:Earnings ratio |
NTA/share | Dividend yield |
|
| fye March | cents | annual avg | dollars | annual avg % |
| 2018 | 33 | 40 | 1.3 | 1.5 |
| 2019 | 37 | 43 | 1.5 | 0.9 |
| 2020 | 50 | 61 | 1.6 | 0.5 |
| 2021 | 91 | 35 | 2.5 | 1.0 |
| 2022 | 65 | 37 | 3.1 | 1.6 |
| 2023 | 43 | 57 | 2.7 | 2.3 |
| 2024 | 23 | 132 | 2.7 | 1.9 |
| 2025 | 64 | 55 | 2.8 | 1.7 |
Description of trading activities
Fisher & Paykel Healthcare is a manufacturer, designer and marketer of products and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnea. Fisher & Paykel Healthcare has a purpose of improving care and outcomes through inspired, world-leading healthcare solutions.
CEO profile
Lewis Gradon became Managing Director and chief Executive Officer in April 2016. Before that, Gradon spent 15 years as Senior Vice President – Products & Technology, and six years as General Manager – Research and Development. During his 37-year tenure with Fisher & Paykel Healthcare, he has held various engineering positions overseeing the development of arange of product, manufacturing, quality, intellectual property, supply chain, and clinical research functions.
Chairman profile
Before joining Fisher and Paykel Neville Mitchell was the Chief financial officer and company secretary of Cochlear Limited. He had this role from 1995 to 2017. Mitchell is also a non-executive director of Sonic Healthcare, and Sigma Healthcare. Mitchell is a former director for a number of other companies within the healthcare industry, while also serving on the New South Wales Medical Devices Fund.
Links:
| Company website: | https://www.fphcare.com/nz/ |
| Investor information: | https://www.fphcare.com/nz/our-company/investor/ |
| NZX listing: | https://www.nzx.com/companies/FPH |
| Annual reports: | https://www.fphcare.com/nz/our-company/investor/ |